Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032281 | 0.89 | ALDH1A1 (0.47) | MRGPRX4GAAL3MBTL1POLBALDH1A1 | |
| SCHEMBL569778 | 0.89 | ALDH1A1 (0.47) | MRGPRX4GAAL3MBTL1POLBALDH1A1 | |
| SCHEMBL30853881 | 0.84 | BRD4 (0.52) | MRGPRX4CYP2A6MAOAMAOBPOLB | |
| SCHEMBL28041457 | 0.80 | MAOA (0.56) | MRGPRX4CYP2A6MAOAMAOBHSD17B10 | |
| SCHEMBL5886388 | 0.80 | PTPRC (0.48) | MRGPRX4CYP2A6MAOAMAOBL3MBTL1 | |
| SCHEMBL11007908 | 0.79 | HSP90AA1 (0.51) | CYP2A6MAOAMAOBL3MBTL1ALDH1A1 | |
| SCHEMBL6808475 | 0.79 | BRD4 (0.45) | MRGPRX4CYP2A6MAOAMAOBHSD17B10 | |
| SCHEMBL3613341 | 0.79 | CXCR5 (0.53) | MRGPRX4L3MBTL1ALDH1A1HSD17B10GFER | |
| SCHEMBL15556851 | 0.77 | SLC22A6 (0.43) | MRGPRX4GAAMAOAMAOBL3MBTL1 | |
| SCHEMBL14840327 | 0.77 | MRGPRX4 (0.39) | MRGPRX4GAACYP2A6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120253046-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-2499137-A1 | PALONOSETRON METABOLITES | Helsinn Healthcare S.A. (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058427-A1 | PALONOSETRON METABOLITES | HELSINN HEALTHCARE S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
| US-5492914-A | ADMINISTERING TO TREAT A CONDITION CHOSEN FROM EMESIS, PSYCHOSIS, ANXIETY/DEPRESSIVE STATE, HYPERTENSION, ARRHYTHMIA AND PAIN | SYNTEX (U.S.A.) INC. (US) | 1996-02-20 | — | — | US | disclosed |
| US-4111997-A | ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY | TAKEDA CHEMICAL COMPANY, LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4007225-A | ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-02-08 | — | — | US | disclosed |
| US-3953500-A | ANTIPYRETICS, ANALGESICS, ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253046-A1 | PALONOSETRON METABOLITES | CYP3A5, MC2R, CYP21A2 | MRGPRX4 161/4885GAA 4095/4885CYP2A6 120/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | MRGPRX4 1366/4885GAA 331/4885CYP2A6 86/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | MRGPRX4 1845/4885GAA 1877/4885CYP2A6 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.